FEATURED STORY |
![]() |
||
|
PEGASYS®/COPEGUS® Show Benefit
in Hard-to-Treat Latino Population with Hepatitis C
|
|||
FEATURED STORY |
![]() |
||
|
HCV Replication and Targets for Antiviral Therapy
HCV RNA Replication Process - Possible Mechanism to Inhibit HCV RNA Replication
|
|||
FEATURED STORY |
![]() |
||
|
Three Studies Presented at 43rd EASL Showed
Higher SVR for Peginterferon Alfa-2a (PEGASYS) Plus Ribavirin Than Peginterferon Alfa-2b Plus Ribavirin in Treating Hepatitis C
|
|||
FEATURED STORY |
![]() |
||
|
Roche’s Investigational Hepatitis C Polymerase Inhibitor, R1626
Demonstrated Significant End-of-Treatment Response in Phase IIa Study
|
|||
FEATURED STORY |
![]() |
||
|
IMPORTANT: Drug Warning Update
to PEGASYS and COPEGUS Package Inserts
|
|||
| Press Releases | Featured Story Archive | ||
| News | Important Drug Update | ||
| Treatment Algorithm | |||
| Prescribing Information | |||
| Clinical Trials |

|
| |||||||||
|
| |||||||||